US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

The Aaron's Company, Inc.

10.09

+0.0000

Volume:- -

Turnover:- -

Market Cap:309.89M

PE:-7.25

High:10.09

Open:10.09

Low:10.09

Close:10.09

Loading ...

Overview Company News Filings

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Johnson & Johnson (NYSE:JNJ) Presents Promising Nipocalimab Data At AAN Annual Meeting

Simply Wall St.

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Press Release: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

SNBL’s SNLD to Present Nasal Levodopa Study at AAN 2025

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AAN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAN\",,,,,undefined,":{"symbol":"AAN","market":"US","secType":"STK","nameCN":"The Aaron's Company, Inc.","latestPrice":10.09,"timestamp":1745524800000,"preClose":10.09,"halted":0,"volume":0,"delay":0,"floatShares":29872074,"shares":30712772,"eps":-1.391109,"marketStatus":"Pre-Mkt","change":0,"latestTime":"04-25 05:43:52 EDT","open":10.09,"high":10.09,"low":10.09,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.391109,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745587800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":10.09,"dividendRate":0.049554,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAN\",,,,,undefined,":{"symbol":"AAN","floatShares":29872074,"roa":"2.18%","roe":"-6.22%","lyrEps":0.091721,"shares":30712772,"dividePrice":0.5,"high":10.09,"amplitude":0,"preClose":10.09,"low":10.09,"week52Low":6.622,"pbRate":"0.47","psRate":"0.15","week52High":11.9,"institutionHeld":0.9259,"latestPrice":10.09,"eps":-1.391109,"divideRate":0.049554,"volume":0,"delay":0,"ttmEps":-1.391109,"open":10.09,"prevYearClose":10.88},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524303052","title":"UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524303052","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524303052?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:00","pubTimestamp":1743678000,"startTime":"0","endTime":"0","summary":"24 scientific abstracts reflect UCB's ongoing commitment to improving outcomes for people living with neurological conditions, including rare epilepsies Dravet syndrome and Lennox-Gastaut syndrome, as well as generalized myasthenia gravis and thymidine kinase 2 deficiency.Research includes disease course data of untreated patients with thymidine kinase 2 deficiency from largest international dataset.Also features new data on generalized myasthenia gravis treatments RYSTIGGO1  and ZILBRYSQ2  including an open-label extension study investigating rozanolixizumab self-administration and a phase 3 study on the effect of zilucoplan on specific outcome scores.\"We at UCB are deeply committed to driving innovation to improve the treatment and care of people living with severe neurological and neuromuscular conditions such as epilepsy, gMG, and TK2d. The data presented at AAN is a testament to our dedication to exploring new frontiers of science and improving care in areas of high unmet need. It","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ucb-presents-latest-research-across-110000212.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ucb-presents-latest-research-across-110000212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4135","UCBJY","AAN","SD","BK4107","BK4585","IE00BD6J9T35.USD","BK4178","UCBJF","CNS","BK4007","BK4168","MP","BK4117","UCB","BK4213","BK4588","FFA","BK4211"],"gpt_icon":0},{"id":"2524519941","title":"Immunic, Inc. to Participate in Scientific and Industry Conferences in April","url":"https://stock-news.laohu8.com/highlight/detail?id=2524519941","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524519941?lang=en_us&edition=fundamental","pubTime":"2025-04-01 18:30","pubTimestamp":1743503400,"startTime":"0","endTime":"0","summary":"NEW YORK, April 1, 2025 /PRNewswire/ --Immunic,Inc.,a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in April:. April 5-9: American Academy of Neurology  2025 Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in San Diego, California. The team will be available throughout the event at booth #2233.Cautionary Statement Regarding Forward-Looking StatementsThis press release contains \"forward-looking statements\" that involve substantial risks and uncertainti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/immunic-inc-participate-scientific-industry-103000570.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunic-inc-participate-scientific-industry-103000570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AAN","BK4178","IMUX"],"gpt_icon":0},{"id":"2523917896","title":"ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917896","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917896?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease. PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026. CAMBRIDGE, Massachusetts, March 31, 2025  -- ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease , amyotrophic lateral sclerosis  and multiple system atrophy , today announced financial results for the fiscal year ended December 31, 2024 and provided a corporate update.Based on the encouraging results from the Phase 1a study of PMN310, ProMIS initiated a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/promis-neurosciences-announces-full-2024-110000013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IP","BK4143","LU1481599808.USD","LU0757428866.USD","BK4023","BK4139","LU0053671581.USD","LU1169590202.USD","LU2125909916.SGD","AAN","LU0728928796.USD","BK4178","IE00B3T34201.USD","LU1923622291.USD","BK4588","PIPE","BK4218","LU1169589451.USD","MSA","LU2125909759.SGD","PMN","PD","LU1481600234.SGD","BK4181","PK","LU1487256676.USD","LU1815336091.USD","BK4136","LU2211815571.USD","LU2463526074.USD","BK4585"],"gpt_icon":0},{"id":"2522587018","title":"Johnson & Johnson (NYSE:JNJ) Presents Promising Nipocalimab Data At AAN Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2522587018","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522587018?lang=en_us&edition=fundamental","pubTime":"2025-03-28 01:21","pubTimestamp":1743096066,"startTime":"0","endTime":"0","summary":"Johnson & Johnson experienced an 11% price increase over the last quarter. This movement coincided with several corporate developments, including the presentation of breakthrough research on nipocalimab at the American Academy of Neurology meeting, and the announcement of FDA fast track designations for its treatments. Additionally, the potential acquisition talks of Intra-Cellular Therapies and strong sales figures in Q4 2024 were pivotal in maintaining investor interest. Launches of new data concerning products like RYBREVANT and TREMFYA underscore the company's ongoing innovation amid fluctuating market conditions, evidenced by tariff uncertainties impacting broader indexes like the Dow Jones and S&P 500.View our complete analysis and fair value estimate and you decide.Find companies with promising cash flow potential yet trading below their fair value.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-presents-172106957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1074936037.SGD","LU2592432038.USD","LU0320765646.SGD","NYSE","IE00BGHQF631.EUR","IE00BVYPNW00.USD","LU2505996681.GBP","LU1914381329.SGD","LU1023059063.AUD","BK4534","BK4007","LU0058720904.USD","LU1032955483.USD","LU2430703178.SGD","LU1059921491.USD","LU0795875169.SGD","LU1061106388.HKD","LU0882574055.USD","LU2468319806.SGD","IE00BVYPNV92.GBP","AAN","LU1430594728.SGD","LU0122379950.USD","LU1894683348.USD","LU2129689514.USD","LU1674673428.USD","LU1674673691.USD","LU0640476718.USD","JNJ","LU1929549753.HKD","IE00BDGV0183.EUR","IE00BJT1NW94.SGD","LU1066051811.HKD","LU2133065610.SGD","LU1894683264.USD","IE00B42XCP33.USD","LU1221951129.SGD","LU1732799900.SGD","LU1244550577.SGD","LU2129689431.USD","LU0889566641.SGD","SG9999001440.SGD","LU0203347892.USD","LU1066051225.USD","LU2430703095.HKD","IE00B19Z3B42.SGD","LU0792757196.USD","LU0234570918.USD","LU0345769128.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2522290543","title":"Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology","url":"https://stock-news.laohu8.com/highlight/detail?id=2522290543","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522290543?lang=en_us&edition=fundamental","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"DUBLIN, March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc.   today announced new analyses of the initial Phase 3 program of ampreloxetine  supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology  Meeting, taking place April 5-9, 2025, in San Diego, California. Results from these initial studies led to the initiation of a Phase 3 confirmatory study  addressingnOH in patients with multiple system atrophy, which is currently ongoing.Analyses will be presented consecutively in a platform session on Monday, April 7, 2025, starting at 11:15 AM Pacific Daylight Time :. NET-Inhibition with Ampreloxetine, Blood Pressure, and Catecholamines in Patients with Neurogenic Orthostatic Hypotension","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/theravance-biopharma-present-ampreloxetine-analyses-100000154.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/theravance-biopharma-present-ampreloxetine-analyses-100000154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4107","BK4007","BK4117","LU1815336091.USD","LU1923622291.USD","TBPH","BK4143","LU0728928796.USD","LU2125909759.SGD","LU0757428866.USD","BK4178","LU2125909916.SGD","LU2211815571.USD","MSA","LU0053671581.USD","AAN"],"gpt_icon":0},{"id":"2522804933","title":"New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522804933","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522804933?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:03","pubTimestamp":1742990580,"startTime":"0","endTime":"0","summary":"Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+. Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-ADLb and QMG scores from the ongoing open-label extension  of the Vivacity-MG3 study. Johnson & Johnson filed a Biologics License Application  for nipocalimab in August 2024 and was granted U.S. FDA Priority Review for the treatment of gMG. Real-world studies highlight the unmet need of patients living with gMG, including those who are pregnant or receiving steroids. Oral and poster presentations include data from the pivotal Phase 3 Vivacity-MG3 study of nipocalimab in gMG, which was included in the U.S. Biologics License Application  for nipocalimab:. Data evaluating nipocalimab using the clinician-administered QMGa assessment score demonstrat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nipocalimab-data-real-world-research-120300965.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nipocalimab-data-real-world-research-120300965.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PT","LU2347655156.SGD","LU1506573853.SGD","JNJ","LU1894683264.USD","LU1914381329.SGD","OCS","MG","LU0912757837.SGD","LU2129689514.USD","D","BK4581","IE00B19Z4B17.USD","LU0289739699.SGD","IE00BMQBXF63.USD","LU1066051498.USD","BK4568","LU0320765646.SGD","LU1244550494.USD","LU0345770993.USD","IE00BVYPNW00.USD","LU1162221912.USD","LU2129689605.HKD","LU2129689431.USD","LU1066051811.HKD","IE00B7SZL793.SGD","AAN","LU2505996681.GBP","LU1221951046.USD","BK4534","LU0795875169.SGD","LU1244550221.USD","LU2112291526.USD","LU2592432038.USD","IE00BZ18W340.USD","IE00BMG7P694.USD","IE00B7SZLL34.SGD","IE00BGHQF631.EUR","LU1935042991.SGD","IE00B42XCP33.USD","IE00B3PB1722.GBP","LU0203345920.USD","LU1929549753.HKD","LU0466842654.USD","IE00BMG7P819.SGD","LU1066053197.SGD","IE00BSNM7G36.USD","LU0345770308.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2522062797","title":"Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2522062797","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522062797?lang=en_us&edition=fundamental","pubTime":"2025-03-25 14:15","pubTimestamp":1742883300,"startTime":"0","endTime":"0","summary":"Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta in people with relapsing multiple sclerosis. Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis  patients to be presented. Additional presentations highlight the Novartis neuroscience pipeline, including remibrutinib for RMS and iptacopan for generalized myasthenia gravis. Basel, March 25, 2025 – Novartis will present data from studies across its neuroscience portfolio, including seven-year disability outcomes and safety data from the ALITHIOS open-label extension trial of Kesimpta  in people with relapsing multiple sclerosis , at the American Academy of Neurology  2025 Annual Meeting inSan Diego from April 5-9,2025. Additional data on Kesimpta and pipeline assets including remibrutinib and iptacopan will also be highlighted.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-present-data-aan-including-061500982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211331839.USD","PT","BK4532","IE00BFTCPJ56.SGD","BK4585","BK4166","AAN","IE0002141913.USD","IE00B2B36J28.USD","BK4588","IE00B4R5TH58.HKD","BK4007","LU0070302665.USD","LU0320765489.SGD","BK4178","BK4578","IE0009355771.USD","LU0208291251.USD","IE00BJT1NW94.SGD","NVS","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2521745072","title":"Press Release: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2521745072","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521745072?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024. -- Advancing a broad, potential best-in-class orexin receptor 2 . agonist franchise with key data readouts expected in 2025. -- ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy. type 1 , narcolepsy type 2  and idiopathic hypersomnia.  well underway and on track with data expected across all. three indications in 2025 with first-in-class potential in NT2 and. Dr. Saha concluded, \"In addition to the transformational potential of ORX750 for individuals living with sleep-wake disorders, we see tremendous opportunity with our follow-up OX2R agonists that are being advanced for the treatment of EDS, impaired attention, cognitive deficits and fatigue in neurological, neurodegenerative and neuropsychiatric disorders. ORX142 is prog","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4597","BK4218","BK4022","BK4535","BK4139","BK4588","BK4539","BK4215","BK4085","CNTA","MSL","BK4585","AAN","R","ESS","BK4178","BK4563","BK4510","BK4232","BK4181","IH","NSS","PK"],"gpt_icon":0},{"id":"2521730353","title":"SNBL’s SNLD to Present Nasal Levodopa Study at AAN 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521730353","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521730353?lang=en_us&edition=fundamental","pubTime":"2025-03-24 10:52","pubTimestamp":1742784729,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Shin Nippon Biomedical Laboratories, Ltd. ( ($JP:2395) ). SNBL’s subsidiary, SNLD, will present findings from a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/snbls-snld-to-present-nasal-levodopa-study-at-aan-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/snbls-snld-to-present-nasal-levodopa-study-at-aan-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4178","AAN"],"gpt_icon":0},{"id":"2521462404","title":"Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2521462404","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521462404?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:00","pubTimestamp":1742554800,"startTime":"0","endTime":"0","summary":"BOSTON and SAN DIEGO, March 21, 2025  -- Rapport Therapeutics, Inc.  , a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced two encore poster presentations at the 2025 American Academy of Neurology  Annual Meeting, taking place from April 5 to April 9, 2025, in San Diego, California. The data from these posters was originally presented at the American Epilepsy Society  Annual Meeting in December 2024.The presentations will highlight the company’s ongoing research and development of RAP-219, a clinical-stage AMPA receptor  negative allosteric modulator  currently in Phase 2 development for the treatment of refractory focal epilepsy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rapport-therapeutics-present-data-2025-110000111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","AFG","IE00B19Z3581.USD","LU1093756325.SGD","IE0002270589.USD","AAN","LU1093756168.USD","IE00B19Z3B42.SGD","BK4139","BK4117","RAPP","BK4178","LU0061475181.USD","BK4105","BK4519","AES","IE00B7SZLL34.SGD","BK4585","LENZ","BK4107"],"gpt_icon":0},{"id":"2519183454","title":"UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS","url":"https://stock-news.laohu8.com/highlight/detail?id=2519183454","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519183454?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:00","pubTimestamp":1741870800,"startTime":"0","endTime":"0","summary":"Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing*. The Phase 3 MINT trial, which was a randomized-control trial, evaluated UPLIZNA in muscle-specific kinase autoantibody-positive  and AChR+ gMG patients, with the MuSK+ group followed for 26 weeks and the AChR+ group followed for 52 weeks. The trial demonstrated continued improvement in efficacy of UPLIZNA compared to placebo  as measured by the change in baseline of Myasthenia Gravis Activities of Daily Living  score in the AChR+ subpopulation through week 52. Among the AChR+ patients in the UPLIZNA group, 72.3% had a ≥3 point improvement in the MG-ADL score, compared to 45.2% in placebo.1. Change from baseline in the Quantitative Myasthenia Gravis  score was also greater for patients in the UPLIZNA group as compared to placebo at Week 52 . Among the AChR+ patients in the UPLIZNA group, 69.2% improved by ≥3 points in the QMG score, compared to 41.8% in the placebo group.1. \"I'm looking forwa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/uplizna-inebilizumab-cdon-significantly-improves-130000205.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/uplizna-inebilizumab-cdon-significantly-improves-130000205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","BK4585","BK4599","SG9999001440.SGD","LU1057294990.SGD","AAN","IE0002141913.USD","LU1983299246.USD","LU0109394709.USD","BK4581","IE00B2B36J28.USD","MINT","BK4139","BK4533","BK4534","BK4588","IE00B4R5TH58.HKD","LU2112291526.USD","LU1061106388.HKD","LU2242646821.SGD","LU2242652126.USD","LU0868494617.USD","BK4178","BK4550","PML","IE0009355771.USD","LU0320765992.SGD","BK4566","LU1571399168.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU1023059063.AUD","LU0122379950.USD","AMGN","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2519880110","title":"ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2519880110","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519880110?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Massachusetts , March  13, 2025  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042031/0/en/ProMIS-Neurosciences-Showcases-Preclinical-Data-on-Platform-Derived-Vaccines-for-Neurodegenerative-Diseases-at-the-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4178","BK4143","LU0757428866.USD","LU2125909759.SGD","LU2211815571.USD","MSA","LU1815336091.USD","AAN","BK4117","LU1923622291.USD","BK4107","LU0728928796.USD","LU0053671581.USD","LU2125909916.SGD"],"gpt_icon":0},{"id":"2517127541","title":"argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517127541","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517127541?lang=en_us&edition=fundamental","pubTime":"2025-03-07 14:00","pubTimestamp":1741327200,"startTime":"0","endTime":"0","summary":"Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART HytrulogMG patients on VYVGART achieve rapid, substantial, and sustained efficacy acro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038734/0/en/argenx-Highlights-FcRn-Leadership-with-Long-term-Data-and-Transformational-Patient-Outcomes-at-the-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4156","BK4178","AAN","BK4117","BK4107"],"gpt_icon":0},{"id":"2517191113","title":"Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517191113","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517191113?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:14","pubTimestamp":1741295640,"startTime":"0","endTime":"0","summary":"BOSTON and LONDON, March 06, 2025  -- Centessa Pharmaceuticals plc , a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 , narcolepsy type 2  and idiopathic hypersomnia , will be presented in a poster sessionat the American Academy of Neurology  2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial  in participants with NT1, NT2 and IH.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/centessa-pharmaceuticals-announces-poster-presentation-211400184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4178","BK4539","BK4117","BK4139","BK4107","BK4535","BK4085","BK4510","BK4563","AFG","CNTA","AAN","IH"],"gpt_icon":1},{"id":"2516633701","title":"Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633701","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516633701?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License App","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035589/0/en/Annexon-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-Portfolio-Progress-and-Key-Anticipated-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2458330243.SGD","LU0127658192.USD","LU0109392836.USD","LU1803068979.SGD","LU1951198990.SGD","LU1852331112.SGD","LU0889565833.HKD","BK4097","LU1242518857.USD","LU2360106780.USD","BK4512","GFS","BK4139","BK4605","LU1989764664.SGD","LU1242518931.SGD","LU0823434583.USD","LU0081259029.USD","PRGS","AAN","LU0642271901.SGD","BK4178","LU0823421333.USD","LU0198837287.USD","BK4588","LU0719512351.SGD","BK4575","LU1064131342.USD","LU0823421416.USD","ANNX","IE00B5949003.HKD","LU0390134368.USD","BK4141","LU1951200564.SGD","BK4532","BK4554","LU0823434740.USD","LU0082616367.USD","IE00BMPRXN33.USD","LU0979878070.USD","BK4534","BK4543","BK4566","LU2264538146.SGD","LU0056508442.USD","BK4573","BK4585","LU1988902786.USD","IE00BMPRXR70.SGD"],"gpt_icon":1},{"id":"2514585663","title":"Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514585663","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514585663?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690300,"startTime":"0","endTime":"0","summary":"Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb.  27,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3034294/0/en/Athira-Pharma-Reports-Full-Year-2024-Financial-Results-and-Pipeline-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AAN","BK4110","BK4178","ATHA","AAIC"],"gpt_icon":0},{"id":"2508178905","title":"NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th","url":"https://stock-news.laohu8.com/highlight/detail?id=2508178905","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508178905?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:05","pubTimestamp":1738616700,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., Feb.  03, 2025  (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/03/3019857/0/en/NeuroPace-Announces-Upcoming-Oral-Presentation-of-Data-from-the-Post-Approval-Study-of-the-RNS-System-at-the-American-Academy-of-Neurology-2025-Annual-Meeting-Being-Held-April-5th-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["POST","BK4107","AAN","BK4212","BK4117","BK4178","AFG","NPCE"],"gpt_icon":0},{"id":"2481506005","title":"Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2481506005","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481506005?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":"DALLAS, November 05, 2024----Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals , formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board  to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight’s management team to provide strategic guidance and critical expert insights into the development of STAR-001 in CNS and brain tumors for both children and adults.\"The establishment of the SAB represents a significant advancement for Starlight, and we are honored to be joined by such accomplished scientific experts. We look forward to drawing upon the deep subject matter expertise of Drs. Berger, DeAngelis, Grossman and Laterra, to shape the development path of STAR-001,\" said Dr. Marc Chamberlain, M.D., Starlight’s Chief Medical Officer. \"We also extend congratulations to Drs. Berger and Grossman on being recipients of the prestigiou","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3lYwz6JWw6lih0fUkzJpOQ--~B/aD0yNzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8032aedd176fa65703ac7c4cdc0808a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3lYwz6JWw6lih0fUkzJpOQ--~B/aD0yNzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8032aedd176fa65703ac7c4cdc0808a6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/starlight-therapeutics-announces-inaugural-members-130000701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LTRN","AAN","BK4178","LENZ"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-10-04","symbol":"AAN","reason":null,"defaultRemindTime":1728048600000,"announcedDate":"2024-09-20","type":"delisting","dateTimestamp":1728014400000},{"date":"2024-09-13","symbol":"AAN","amount":0.125,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-13","defaultRemindTime":1726234200000,"name":"The Aaron's Company, Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-03","payableDate":"2024-09-13","currency":"USD","dateTimestamp":1726200000000,"payDate":"2024-10-03"},{"date":"2024-08-05","symbol":"AAN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/06","expectedEps":0.03,"defaultRemindTime":1722888000000,"name":null,"time":"Post Market","dateTimestamp":1722830400000,"actualEps":null},{"date":"2024-06-14","symbol":"AAN","amount":0.125,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-06-14","defaultRemindTime":1718371800000,"name":"The Aaron's Company, Inc.","recordDate":"2024-07-03","payableDate":"2024-06-14","currency":"USD","dateTimestamp":1718337600000,"payDate":"2024-07-03"},{"date":"2024-05-06","symbol":"AAN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/03","expectedEps":-0.08,"defaultRemindTime":1715025600000,"name":null,"time":"Post Market","dateTimestamp":1714968000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAN\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-13","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-06-23","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-09-14","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-12-12","recordDate":null,"paymentDate":null,"value":0.03,"currency":"USD"},{"executeDate":"2018-03-22","recordDate":null,"paymentDate":null,"value":0.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":7,"updateTime":1720670400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAN","date":"2024-10-02","current":-7.155926,"percent":0.311436,"low":-226.61145,"twenty":-13.023365,"median":6.536302,"eighty":20.725985,"high":112.497555,"avg":-0.454661,"sd":44.674017,"marketCap":304670698},"quantilePoints":[{"date":"2020-05-01","current":65.500706,"twenty":12.61139,"median":14.504533,"eighty":46.359785,"marketCap":2061438232},{"date":"2020-05-08","current":-7.937042,"twenty":12.622151,"median":14.571174,"eighty":48.522958,"marketCap":2417710345},{"date":"2020-05-15","current":-6.943248,"twenty":12.643672,"median":14.61603,"eighty":50.155943,"marketCap":2114989765},{"date":"2020-05-22","current":-7.53775,"twenty":12.65228,"median":14.634494,"eighty":50.708839,"marketCap":2296081540},{"date":"2020-05-29","current":-8.187709,"twenty":12.66261,"median":14.649576,"eighty":52.834231,"marketCap":2494066205},{"date":"2020-06-05","current":-10.108748,"twenty":12.666915,"median":14.697246,"eighty":55.285946,"marketCap":3079235898},{"date":"2020-06-12","current":-9.660654,"twenty":12.694892,"median":14.714231,"eighty":60.33638,"marketCap":2942741350},{"date":"2020-06-19","current":-9.374494,"twenty":12.706944,"median":14.728744,"eighty":64.235874,"marketCap":2855574041},{"date":"2020-06-26","current":-9.831462,"twenty":12.727173,"median":14.743696,"eighty":68.885595,"marketCap":2994771450},{"date":"2020-07-02","current":-9.922412,"twenty":12.757734,"median":14.760452,"eighty":74.680396,"marketCap":3022475789},{"date":"2020-07-10","current":-9.718329,"twenty":12.780116,"median":14.769223,"eighty":82.671415,"marketCap":2960309955},{"date":"2020-07-17","current":-9.76935,"twenty":12.808093,"median":14.806954,"eighty":91.048411,"marketCap":2975851414},{"date":"2020-07-24","current":-9.968996,"twenty":12.82574,"median":14.866761,"eighty":-10.859861,"marketCap":3036665816},{"date":"2020-07-31","current":-12.701825,"twenty":12.834349,"median":14.893301,"eighty":-10.268021,"marketCap":3542335892},{"date":"2020-08-07","current":-13.074984,"twenty":12.839514,"median":14.903566,"eighty":-10.577251,"marketCap":3646403759},{"date":"2020-08-14","current":-14.062047,"twenty":12.883417,"median":15.075972,"eighty":-10.859861,"marketCap":3921680051},{"date":"2020-08-21","current":-13.655185,"twenty":12.929473,"median":15.897669,"eighty":-11.826229,"marketCap":3808212506},{"date":"2020-08-28","current":-13.703334,"twenty":12.954868,"median":16.208979,"eighty":-12.506339,"marketCap":3821640618},{"date":"2020-09-04","current":-13.39277,"twenty":12.981123,"median":16.624181,"eighty":-12.566525,"marketCap":3735029297},{"date":"2020-09-11","current":-14.247423,"twenty":12.992314,"median":17.026732,"eighty":-12.622378,"marketCap":3973378281},{"date":"2020-09-18","current":-13.662407,"twenty":13.056878,"median":17.41088,"eighty":-12.80968,"marketCap":3810226723},{"date":"2020-09-25","current":-13.096651,"twenty":13.174383,"median":17.72832,"eighty":-13.012871,"marketCap":3652446409},{"date":"2020-10-02","current":-13.525181,"twenty":13.207096,"median":17.868637,"eighty":-13.083651,"marketCap":3771956604},{"date":"2020-10-09","current":-14.379834,"twenty":13.214843,"median":33.338326,"eighty":-13.117837,"marketCap":4010305589},{"date":"2020-10-16","current":-14.322055,"twenty":13.224312,"median":38.979544,"eighty":-13.152023,"marketCap":3994191854},{"date":"2020-10-23","current":-14.134272,"twenty":13.267355,"median":41.25936,"eighty":-13.164982,"marketCap":3941822218},{"date":"2020-10-30","current":-13.18332,"twenty":13.431346,"median":46.359785,"eighty":-13.174612,"marketCap":3676617010},{"date":"2020-11-06","current":-13.890074,"twenty":13.510113,"median":48.066995,"eighty":-13.16406,"marketCap":3873719412},{"date":"2020-11-13","current":-18.86588,"twenty":13.554877,"median":49.399254,"eighty":-13.174612,"marketCap":3949383272},{"date":"2020-11-20","current":-20.234189,"twenty":13.740165,"median":50.045957,"eighty":-13.179304,"marketCap":4235825028},{"date":"2020-11-27","current":-3.0341,"twenty":12.60063,"median":14.406704,"eighty":14.852959,"marketCap":753260750},{"date":"2020-12-04","current":-2.585107,"twenty":12.532192,"median":14.373349,"eighty":14.823056,"marketCap":641791671},{"date":"2020-12-11","current":-2.410953,"twenty":12.484845,"median":14.29399,"eighty":14.806494,"marketCap":598555179},{"date":"2020-12-18","current":-2.470818,"twenty":12.40823,"median":14.223831,"eighty":14.790852,"marketCap":613417723},{"date":"2020-12-24","current":-2.283058,"twenty":12.321715,"median":14.182426,"eighty":14.77668,"marketCap":566803381},{"date":"2020-12-31","current":-2.579665,"twenty":12.263178,"median":14.155973,"eighty":14.768028,"marketCap":640440530},{"date":"2021-01-08","current":-2.747017,"twenty":-12.767253,"median":12.412319,"eighty":14.892168,"marketCap":681988096},{"date":"2021-01-15","current":-2.921171,"twenty":-12.676425,"median":12.394026,"eighty":14.876492,"marketCap":725224588},{"date":"2021-01-22","current":-2.816406,"twenty":-12.623461,"median":12.34668,"eighty":14.868142,"marketCap":699215136},{"date":"2021-01-29","current":-2.304827,"twenty":-12.566525,"median":12.314398,"eighty":14.85756,"marketCap":572207942},{"date":"2021-02-05","current":-2.670824,"twenty":-12.506339,"median":12.260595,"eighty":14.829956,"marketCap":663072131},{"date":"2021-02-12","current":-2.717084,"twenty":-11.826229,"median":12.245531,"eighty":14.807414,"marketCap":674556824},{"date":"2021-02-19","current":-2.880354,"twenty":-10.895798,"median":12.221858,"eighty":14.800053,"marketCap":715091035},{"date":"2021-02-26","current":-2.824769,"twenty":-10.664651,"median":12.178815,"eighty":14.779165,"marketCap":751139845},{"date":"2021-03-05","current":-3.082033,"twenty":-10.291535,"median":12.103491,"eighty":14.768028,"marketCap":819549667},{"date":"2021-03-12","current":-3.265978,"twenty":-10.182396,"median":11.879671,"eighty":14.76305,"marketCap":868462690},{"date":"2021-03-19","current":-3.326435,"twenty":-10.119396,"median":-2.281017,"eighty":14.761535,"marketCap":884538998},{"date":"2021-03-26","current":-3.343157,"twenty":-10.105642,"median":-2.304827,"eighty":14.756348,"marketCap":888985636},{"date":"2021-04-01","current":-3.34573,"twenty":-10.09322,"median":-2.344284,"eighty":14.747146,"marketCap":889669735},{"date":"2021-04-09","current":-3.17079,"twenty":-10.071037,"median":-2.386462,"eighty":14.740245,"marketCap":843151056},{"date":"2021-04-16","current":-3.285273,"twenty":-10.046636,"median":-2.443607,"eighty":14.729751,"marketCap":873593426},{"date":"2021-04-23","current":-3.316144,"twenty":-10.020017,"median":-2.447688,"eighty":14.728744,"marketCap":881802605},{"date":"2021-04-30","current":11.206787,"twenty":-9.991179,"median":-2.446328,"eighty":14.725108,"marketCap":1055511238},{"date":"2021-05-07","current":11.685679,"twenty":-9.968996,"median":-2.40415,"eighty":14.71582,"marketCap":1100615635},{"date":"2021-05-14","current":11.816285,"twenty":-9.960123,"median":-2.352448,"eighty":14.712642,"marketCap":1112916834},{"date":"2021-05-21","current":12.614438,"twenty":-9.922412,"median":-2.317753,"eighty":14.704211,"marketCap":1188090830},{"date":"2021-05-28","current":13.049794,"twenty":-9.922412,"median":-2.283058,"eighty":14.697246,"marketCap":1229094828},{"date":"2021-06-04","current":13.125981,"twenty":-9.917088,"median":-2.227274,"eighty":14.68932,"marketCap":1236270527},{"date":"2021-06-11","current":13.260216,"twenty":-9.867842,"median":11.159624,"eighty":14.667402,"marketCap":1248913426},{"date":"2021-06-18","current":12.57453,"twenty":-9.84699,"median":11.239439,"eighty":14.64187,"marketCap":1184332130},{"date":"2021-06-25","current":11.965032,"twenty":-9.834124,"median":11.357348,"eighty":14.634991,"marketCap":1126926534},{"date":"2021-07-02","current":11.732842,"twenty":-9.829688,"median":11.551444,"eighty":14.634457,"marketCap":1105057735},{"date":"2021-07-09","current":11.174135,"twenty":-9.803955,"median":11.36279,"eighty":14.630291,"marketCap":1052435938},{"date":"2021-07-16","current":10.038588,"twenty":-9.784434,"median":11.319254,"eighty":14.62063,"marketCap":945484414},{"date":"2021-07-23","current":9.724994,"twenty":-9.774674,"median":11.228555,"eighty":14.598088,"marketCap":915948515},{"date":"2021-07-30","current":9.001746,"twenty":-9.75604,"median":11.175949,"eighty":14.583366,"marketCap":943256951},{"date":"2021-08-06","current":8.621347,"twenty":-9.731195,"median":11.141484,"eighty":14.569104,"marketCap":903396422},{"date":"2021-08-13","current":9.117113,"twenty":-9.719216,"median":10.680732,"eighty":14.542881,"marketCap":955345800},{"date":"2021-08-20","current":8.764776,"twenty":-9.702358,"median":10.238148,"eighty":14.515087,"marketCap":918425802},{"date":"2021-08-27","current":8.602638,"twenty":-9.686386,"median":10.004734,"eighty":14.503803,"marketCap":901436068},{"date":"2021-09-03","current":8.371904,"twenty":-9.670858,"median":9.878227,"eighty":14.495035,"marketCap":877258370},{"date":"2021-09-10","current":8.178587,"twenty":-9.661985,"median":9.724994,"eighty":14.487674,"marketCap":857001379},{"date":"2021-09-17","current":8.396849,"twenty":-9.651781,"median":9.151412,"eighty":14.481233,"marketCap":879872175},{"date":"2021-09-24","current":8.580812,"twenty":-9.63226,"median":9.001746,"eighty":14.46099,"marketCap":899148988},{"date":"2021-10-01","current":8.761658,"twenty":-9.601647,"median":8.958094,"eighty":14.437068,"marketCap":918099076},{"date":"2021-10-08","current":8.714887,"twenty":-9.542197,"median":8.892615,"eighty":14.434307,"marketCap":913198191},{"date":"2021-10-15","current":8.56834,"twenty":-9.495613,"median":8.813105,"eighty":14.433387,"marketCap":897842086},{"date":"2021-10-22","current":9.447624,"twenty":-9.47343,"median":8.883261,"eighty":14.431087,"marketCap":989978719},{"date":"2021-10-29","current":7.629357,"twenty":-9.434388,"median":8.8209,"eighty":14.420506,"marketCap":736393147},{"date":"2021-11-05","current":8.350215,"twenty":-9.394459,"median":8.792838,"eighty":14.39847,"marketCap":805971123},{"date":"2021-11-12","current":8.568756,"twenty":-9.349649,"median":8.764776,"eighty":14.382391,"marketCap":827064898},{"date":"2021-11-19","current":8.239314,"twenty":-9.109187,"median":8.724241,"eighty":14.37404,"marketCap":795266819},{"date":"2021-11-26","current":7.847898,"twenty":-8.748937,"median":8.714887,"eighty":14.357938,"marketCap":757486922},{"date":"2021-12-03","current":7.440172,"twenty":-8.524445,"median":8.691502,"eighty":14.306872,"marketCap":718132864},{"date":"2021-12-10","current":7.94249,"twenty":-8.467214,"median":8.668117,"eighty":14.283409,"marketCap":766617064},{"date":"2021-12-17","current":7.844636,"twenty":-8.262243,"median":8.662471,"eighty":14.239703,"marketCap":757172090},{"date":"2021-12-23","current":7.988155,"twenty":-8.187709,"median":8.61667,"eighty":14.234182,"marketCap":771024719},{"date":"2021-12-31","current":8.040344,"twenty":-8.054612,"median":8.608874,"eighty":14.21348,"marketCap":776062038},{"date":"2022-01-07","current":7.74352,"twenty":-8.039083,"median":8.604197,"eighty":14.188176,"marketCap":747412283},{"date":"2022-01-14","current":7.489099,"twenty":-7.937042,"median":8.587048,"eighty":14.176675,"marketCap":722855351},{"date":"2022-01-21","current":6.954164,"twenty":-7.711664,"median":8.580812,"eighty":14.163793,"marketCap":671222826},{"date":"2022-01-28","current":6.771503,"twenty":-7.561264,"median":8.568548,"eighty":14.153212,"marketCap":653592207},{"date":"2022-02-04","current":6.774764,"twenty":-7.498708,"median":8.50598,"eighty":14.13849,"marketCap":653907040},{"date":"2022-02-11","current":6.800859,"twenty":-7.4783,"median":8.402672,"eighty":14.109507,"marketCap":656425699},{"date":"2022-02-18","current":6.85631,"twenty":-7.417075,"median":8.390613,"eighty":14.090805,"marketCap":661777851},{"date":"2022-02-25","current":6.0444,"twenty":-7.399772,"median":8.371904,"eighty":14.073473,"marketCap":664485049},{"date":"2022-03-04","current":6.303647,"twenty":-7.338104,"median":8.35837,"eighty":14.046019,"marketCap":692985107},{"date":"2022-03-11","current":6.154298,"twenty":-7.214323,"median":8.322016,"eighty":14.028536,"marketCap":676566596},{"date":"2022-03-18","current":6.531897,"twenty":-7.133134,"median":8.300596,"eighty":14.016575,"marketCap":718077550},{"date":"2022-03-25","current":6.358874,"twenty":-7.012459,"median":8.278364,"eighty":13.990352,"marketCap":699056405},{"date":"2022-04-01","current":5.853417,"twenty":-6.728961,"median":8.262316,"eighty":13.959988,"marketCap":643489564},{"date":"2022-04-08","current":6.111955,"twenty":-4.797768,"median":8.237829,"eighty":13.929624,"marketCap":671911684},{"date":"2022-04-14","current":6.210723,"twenty":-3.54381,"median":8.229529,"eighty":13.89558,"marketCap":682769573},{"date":"2022-04-22","current":5.94928,"twenty":-3.437831,"median":8.209791,"eighty":13.857395,"marketCap":654028103},{"date":"2022-04-29","current":6.626359,"twenty":-3.415191,"median":8.180601,"eighty":13.79395,"marketCap":630451705},{"date":"2022-05-06","current":6.539213,"twenty":-3.410303,"median":8.142587,"eighty":13.634075,"marketCap":622160328},{"date":"2022-05-13","current":6.452066,"twenty":-3.405158,"median":8.086009,"eighty":13.512696,"marketCap":613868951},{"date":"2022-05-20","current":5.864635,"twenty":-3.380718,"median":8.051782,"eighty":13.496451,"marketCap":557978932},{"date":"2022-05-27","current":6.077659,"twenty":-3.349589,"median":8.001202,"eighty":13.451527,"marketCap":578246741},{"date":"2022-06-03","current":5.961464,"twenty":-3.34573,"median":7.971846,"eighty":13.396862,"marketCap":567191572},{"date":"2022-06-10","current":5.796854,"twenty":-3.345215,"median":7.947382,"eighty":13.321166,"marketCap":551530083},{"date":"2022-06-17","current":5.060951,"twenty":-3.339813,"median":7.90661,"eighty":13.254413,"marketCap":481514015},{"date":"2022-06-24","current":5.222333,"twenty":-3.326435,"median":7.860945,"eighty":13.231199,"marketCap":496868416},{"date":"2022-07-01","current":4.760779,"twenty":-3.316144,"median":7.81528,"eighty":13.22259,"marketCap":452954829},{"date":"2022-07-08","current":4.947983,"twenty":-3.305854,"median":7.76146,"eighty":13.21226,"marketCap":470765934},{"date":"2022-07-15","current":4.734958,"twenty":-3.289903,"median":7.704378,"eighty":13.206235,"marketCap":450498125},{"date":"2022-07-22","current":5.167463,"twenty":-3.28553,"median":7.670129,"eighty":13.197004,"marketCap":491647920},{"date":"2022-07-29","current":7.051656,"twenty":-3.278069,"median":7.648928,"eighty":13.194912,"marketCap":400717386},{"date":"2022-08-05","current":7.214136,"twenty":-3.275239,"median":7.552705,"eighty":13.171694,"marketCap":409950505},{"date":"2022-08-12","current":7.907387,"twenty":-3.267779,"median":7.629357,"eighty":13.156156,"marketCap":449345149},{"date":"2022-08-19","current":7.598674,"twenty":-3.244368,"median":7.653821,"eighty":13.131529,"marketCap":431802221},{"date":"2022-08-26","current":6.932503,"twenty":-3.236907,"median":7.598674,"eighty":13.111469,"marketCap":393946432},{"date":"2022-09-02","current":6.428814,"twenty":-3.219927,"median":7.549929,"eighty":13.107841,"marketCap":365323761},{"date":"2022-09-09","current":6.640038,"twenty":-3.21118,"median":7.533133,"eighty":13.099134,"marketCap":377326816},{"date":"2022-09-16","current":6.612958,"twenty":-3.207321,"median":7.484937,"eighty":13.091152,"marketCap":375787963},{"date":"2022-09-23","current":5.8493,"twenty":-3.205263,"median":7.456481,"eighty":13.087524,"marketCap":332392302},{"date":"2022-09-30","current":5.26437,"twenty":-3.201919,"median":7.440172,"eighty":13.068659,"marketCap":299153071},{"date":"2022-10-07","current":5.145217,"twenty":-3.198832,"median":7.301545,"eighty":13.052696,"marketCap":292382117},{"date":"2022-10-14","current":4.798592,"twenty":-3.190085,"median":7.23794,"eighty":13.04544,"marketCap":272684795},{"date":"2022-10-21","current":4.717352,"twenty":-3.17645,"median":7.204836,"eighty":13.012404,"marketCap":268068236},{"date":"2022-10-28","current":18.856739,"twenty":-3.156126,"median":7.23794,"eighty":13.087524,"marketCap":317962337},{"date":"2022-11-04","current":17.72497,"twenty":-3.141719,"median":7.301545,"eighty":13.115097,"marketCap":298878441},{"date":"2022-11-11","current":20.882972,"twenty":-3.13786,"median":7.440172,"eighty":13.194912,"marketCap":352128668},{"date":"2022-11-18","current":20.171052,"twenty":-3.129627,"median":7.456481,"eighty":13.226034,"marketCap":340124281},{"date":"2022-11-25","current":21.138532,"twenty":-3.119851,"median":7.477233,"eighty":13.381747,"marketCap":356437935},{"date":"2022-12-02","current":22.945713,"twenty":-3.112391,"median":7.528241,"eighty":13.634075,"marketCap":386910608},{"date":"2022-12-09","current":21.412348,"twenty":-3.103901,"median":7.549929,"eighty":13.936064,"marketCap":361055006},{"date":"2022-12-16","current":21.722672,"twenty":-3.091295,"median":7.598674,"eighty":14.030377,"marketCap":366287688},{"date":"2022-12-23","current":20.755191,"twenty":-3.086664,"median":7.653821,"eighty":14.122388,"marketCap":349974034},{"date":"2022-12-30","current":21.813943,"twenty":-3.077344,"median":7.683177,"eighty":14.173455,"marketCap":367826712},{"date":"2023-01-06","current":23.821921,"twenty":-3.05859,"median":7.720687,"eighty":14.234182,"marketCap":401685237},{"date":"2023-01-13","current":26.194986,"twenty":-3.050427,"median":7.750322,"eighty":14.369899,"marketCap":441699859},{"date":"2023-01-20","current":25.884662,"twenty":-3.037365,"median":7.785923,"eighty":14.411305,"marketCap":436467178},{"date":"2023-01-27","current":26.158478,"twenty":-2.983948,"median":7.846267,"eighty":14.435227,"marketCap":441084249},{"date":"2023-02-03","current":28.239473,"twenty":-2.934484,"median":7.860945,"eighty":14.492274,"marketCap":476173994},{"date":"2023-02-10","current":26.724362,"twenty":-2.921987,"median":7.903348,"eighty":14.564964,"marketCap":450626197},{"date":"2023-02-17","current":26.92516,"twenty":-2.910286,"median":7.907387,"eighty":14.628911,"marketCap":454012050},{"date":"2023-02-24","current":25.793391,"twenty":-2.891238,"median":7.922919,"eighty":14.647007,"marketCap":434928154},{"date":"2023-03-03","current":-74.11349,"twenty":-2.922804,"median":7.915153,"eighty":14.672386,"marketCap":391319229},{"date":"2023-03-10","current":-64.718823,"twenty":-3.053692,"median":7.907387,"eighty":14.647007,"marketCap":341715383},{"date":"2023-03-17","current":-54.86022,"twenty":-3.100042,"median":7.890196,"eighty":14.635427,"marketCap":289661964},{"date":"2023-03-24","current":-55.522605,"twenty":-3.13786,"median":7.853226,"eighty":14.634482,"marketCap":293159356},{"date":"2023-03-31","current":-58.235436,"twenty":-3.190085,"median":7.835391,"eighty":14.630291,"marketCap":307483103},{"date":"2023-04-06","current":-57.512015,"twenty":-3.205778,"median":7.782661,"eighty":14.622931,"marketCap":303663437},{"date":"2023-04-14","current":-64.62566,"twenty":-3.237936,"median":7.74352,"eighty":14.604068,"marketCap":341223485},{"date":"2023-04-21","current":-62.214255,"twenty":-3.281671,"median":7.694593,"eighty":14.584286,"marketCap":328491265},{"date":"2023-04-28","current":-29.179552,"twenty":-3.322319,"median":7.658713,"eighty":14.573245,"marketCap":408922246},{"date":"2023-05-05","current":-26.224103,"twenty":-3.349589,"median":7.614015,"eighty":14.548861,"marketCap":367504573},{"date":"2023-05-12","current":-27.701827,"twenty":-3.415191,"median":7.555345,"eighty":14.520365,"marketCap":388213410},{"date":"2023-05-19","current":-28.650218,"twenty":-6.80039,"median":7.533133,"eighty":14.504046,"marketCap":401504155},{"date":"2023-05-26","current":-27.282771,"twenty":-7.358069,"median":7.484937,"eighty":14.497795,"marketCap":382340755},{"date":"2023-06-02","current":-27.018104,"twenty":-7.486286,"median":7.459743,"eighty":14.488594,"marketCap":378631709},{"date":"2023-06-09","current":-31.782113,"twenty":-8.018675,"median":7.446307,"eighty":14.483074,"marketCap":445394525},{"date":"2023-06-16","current":-30.017665,"twenty":-8.467214,"median":7.348842,"eighty":14.468351,"marketCap":420667556},{"date":"2023-06-23","current":-28.716385,"twenty":-9.312382,"median":7.241202,"eighty":14.438908,"marketCap":402431417},{"date":"2023-06-30","current":-31.605668,"twenty":-9.459233,"median":7.224968,"eighty":14.435227,"marketCap":442921828},{"date":"2023-07-07","current":-31.892391,"twenty":-9.591,"median":7.195537,"eighty":14.434307,"marketCap":446939961},{"date":"2023-07-14","current":-33.083393,"twenty":-9.670858,"median":7.136824,"eighty":14.432927,"marketCap":463630665},{"date":"2023-07-21","current":-34.340562,"twenty":-9.731195,"median":7.111232,"eighty":14.430627,"marketCap":481248630},{"date":"2023-07-28","current":-33.921505,"twenty":-9.803955,"median":7.051837,"eighty":14.415905,"marketCap":475375975},{"date":"2023-08-04","current":-188.365396,"twenty":-9.879821,"median":7.029992,"eighty":14.394353,"marketCap":405927428},{"date":"2023-08-11","current":-189.224858,"twenty":-9.963672,"median":6.998198,"eighty":14.380528,"marketCap":407779569},{"date":"2023-08-18","current":-177.90861,"twenty":-10.056396,"median":6.986782,"eighty":14.372659,"marketCap":383393054},{"date":"2023-08-25","current":-170.316697,"twenty":-10.152227,"median":6.952533,"eighty":14.334015,"marketCap":367032481},{"date":"2023-09-01","current":-172.895082,"twenty":-11.528064,"median":6.932503,"eighty":14.300431,"marketCap":372588902},{"date":"2023-09-08","current":-145.392302,"twenty":-12.623461,"median":6.905237,"eighty":14.272827,"marketCap":313320410},{"date":"2023-09-15","current":-149.25988,"twenty":-13.033575,"median":6.884571,"eighty":14.238323,"marketCap":321655042},{"date":"2023-09-22","current":-152.697728,"twenty":-13.168875,"median":6.85631,"eighty":14.225901,"marketCap":329063603},{"date":"2023-09-29","current":-152.41124,"twenty":-13.297434,"median":6.830215,"eighty":14.203358,"marketCap":328446223},{"date":"2023-10-06","current":-140.665261,"twenty":-13.435141,"median":6.802519,"eighty":14.183576,"marketCap":303133638},{"date":"2023-10-13","current":-136.797683,"twenty":-13.525181,"median":6.773134,"eighty":14.170234,"marketCap":294799007},{"date":"2023-10-20","current":-133.646323,"twenty":-13.584405,"median":6.745664,"eighty":14.158733,"marketCap":288007825},{"date":"2023-10-27","current":23.778109,"twenty":-13.598368,"median":6.745664,"eighty":14.167014,"marketCap":221707087},{"date":"2023-11-03","current":23.680524,"twenty":-13.577664,"median":6.774764,"eighty":14.236942,"marketCap":220797209},{"date":"2023-11-10","current":22.346868,"twenty":-13.547812,"median":6.803199,"eighty":14.372659,"marketCap":208362201},{"date":"2023-11-17","current":27.909189,"twenty":-13.52807,"median":6.836739,"eighty":14.430627,"marketCap":260225282},{"date":"2023-11-24","current":28.917563,"twenty":-13.525181,"median":6.85631,"eighty":14.437068,"marketCap":269627361},{"date":"2023-12-01","current":28.657338,"twenty":-13.505446,"median":6.884571,"eighty":14.497795,"marketCap":267201018},{"date":"2023-12-08","current":34.02449,"twenty":-13.470998,"median":6.905237,"eighty":14.573245,"marketCap":317244342},{"date":"2023-12-15","current":38.123042,"twenty":-13.460384,"median":6.940627,"eighty":14.631672,"marketCap":355459243},{"date":"2023-12-22","current":36.333991,"twenty":-13.435141,"median":6.954164,"eighty":14.677371,"marketCap":338778135},{"date":"2023-12-29","current":36.333991,"twenty":-13.404807,"median":6.970474,"eighty":14.704211,"marketCap":338778135},{"date":"2024-01-05","current":36.952027,"twenty":-13.397585,"median":6.991083,"eighty":14.719535,"marketCap":344540700},{"date":"2024-01-12","current":35.423202,"twenty":-13.386992,"median":7.016542,"eighty":14.743005,"marketCap":330285935},{"date":"2024-01-19","current":33.308869,"twenty":-13.35425,"median":7.040824,"eighty":14.762852,"marketCap":310571898},{"date":"2024-01-26","current":34.870223,"twenty":-13.297434,"median":7.052018,"eighty":14.7972,"marketCap":325129956},{"date":"2024-02-02","current":33.66668,"twenty":-13.239655,"median":7.119356,"eighty":14.868142,"marketCap":313908120},{"date":"2024-02-09","current":33.991961,"twenty":-13.181312,"median":7.140086,"eighty":14.902766,"marketCap":316941049},{"date":"2024-02-16","current":35.228033,"twenty":-13.176456,"median":7.204836,"eighty":15.530992,"marketCap":328466178},{"date":"2024-02-23","current":33.146228,"twenty":-13.171283,"median":7.231454,"eighty":16.007704,"marketCap":309055434},{"date":"2024-03-01","current":83.351439,"twenty":-13.159245,"median":7.254249,"eighty":16.944381,"marketCap":235301113},{"date":"2024-03-08","current":77.221075,"twenty":-13.139022,"median":7.397562,"eighty":17.504731,"marketCap":217995096},{"date":"2024-03-15","current":74.74742,"twenty":-13.092318,"median":7.453219,"eighty":17.739361,"marketCap":211011966},{"date":"2024-03-22","current":81.364368,"twenty":-13.05428,"median":7.477233,"eighty":17.972015,"marketCap":229691610},{"date":"2024-03-28","current":80.387995,"twenty":-12.971462,"median":7.50867,"eighty":18.290855,"marketCap":226935310},{"date":"2024-04-05","current":78.760708,"twenty":-12.865396,"median":7.544513,"eighty":18.783722,"marketCap":222341478},{"date":"2024-04-12","current":77.458878,"twenty":-12.701825,"median":7.583029,"eighty":19.185317,"marketCap":218666412},{"date":"2024-04-19","current":79.303137,"twenty":-12.659492,"median":7.648928,"eighty":20.171052,"marketCap":223872755},{"date":"2024-04-26","current":79.411623,"twenty":-12.569414,"median":7.683177,"eighty":20.718683,"marketCap":224179011},{"date":"2024-05-03","current":73.661874,"twenty":-12.562192,"median":7.736996,"eighty":20.882972,"marketCap":207947470},{"date":"2024-05-10","current":-9.41993,"twenty":-12.422559,"median":7.694593,"eighty":20.882972,"marketCap":227547821},{"date":"2024-05-17","current":-9.55939,"twenty":-10.931734,"median":7.658713,"eighty":20.755191,"marketCap":230916631},{"date":"2024-05-24","current":-9.064939,"twenty":-10.752052,"median":7.614015,"eighty":20.736937,"marketCap":218972668},{"date":"2024-05-31","current":-9.77492,"twenty":-10.40245,"median":7.561364,"eighty":20.736937,"marketCap":236122975},{"date":"2024-06-07","current":-10.751145,"twenty":-10.751145,"median":7.538026,"eighty":20.722334,"marketCap":259704647},{"date":"2024-06-14","current":-9.812955,"twenty":-10.735931,"median":7.489099,"eighty":20.685825,"marketCap":237041741},{"date":"2024-06-21","current":-13.023365,"twenty":-10.751689,"median":7.469528,"eighty":20.598203,"marketCap":314592404},{"date":"2024-06-28","current":-12.984217,"twenty":-10.787988,"median":7.459743,"eighty":20.532488,"marketCap":313646735},{"date":"2024-07-05","current":-13.036414,"twenty":-12.56797,"median":7.440172,"eighty":20.433914,"marketCap":314907627},{"date":"2024-07-12","current":-12.997266,"twenty":-12.950249,"median":7.23794,"eighty":20.433914,"marketCap":313961958},{"date":"2024-07-15","current":-13.036414,"twenty":-12.981666,"median":7.224968,"eighty":20.433914,"marketCap":314907627},{"date":"2024-08-02","current":-13.127761,"twenty":-13.007706,"median":7.086518,"eighty":20.725985,"marketCap":317114187},{"date":"2024-08-09","current":-7.228062,"twenty":-13.023365,"median":7.029992,"eighty":20.725985,"marketCap":307741975},{"date":"2024-08-16","current":-7.271344,"twenty":-13.023365,"median":6.970474,"eighty":20.725985,"marketCap":309584741},{"date":"2024-08-23","current":-7.26413,"twenty":-13.023365,"median":6.9205,"eighty":20.725985,"marketCap":309277614},{"date":"2024-08-30","current":-7.278558,"twenty":-13.023365,"median":6.879843,"eighty":20.725985,"marketCap":309891869},{"date":"2024-09-06","current":-7.206421,"twenty":-13.023365,"median":6.830215,"eighty":20.725985,"marketCap":306820592},{"date":"2024-09-13","current":-7.292985,"twenty":-13.023365,"median":6.773134,"eighty":20.725985,"marketCap":310506124},{"date":"2024-09-20","current":-7.242489,"twenty":-13.023365,"median":6.654179,"eighty":20.725985,"marketCap":308356230},{"date":"2024-09-27","current":-7.235276,"twenty":-13.023365,"median":6.602126,"eighty":20.725985,"marketCap":308049103},{"date":"2024-10-02","current":-7.155926,"twenty":-13.023365,"median":6.536302,"eighty":20.725985,"marketCap":304670698}],"updateTime":1745574232219}}}